Kalinsky Kevin, Lim Emerson A, Andreopoulou Eleni, Desai Avni M, Jin Zhezhen, Tu Yifan, Hibshoosh Hanina, Wang Antai, Greenlee Heather, Crew Katherine D, Maurer Matthew, Sparano Joseph A, Hershman Dawn L
Department of Medicine, College of Physicians and Surgeons,1.
Cancer Invest. 2014 Nov;32(9):439-44. doi: 10.3109/07357907.2014.958232. Epub 2014 Sep 25.
Hispanic women have higher breast cancer mortality compared to non-Hispanic whites. We evaluated for Proliferation Axis Score differences, as determined by Oncotype Dx, in Hispanic and non-Hispanic white women with newly diagnosed breast cancer. We matched 219 women, based upon age, stage, and nodal status. Compared to non-Hispanic whites, Hispanic women with hormone-sensitive, HER2-negative early-stage breast cancer had a higher Proliferation Axis Score. No differences were seen in Recurrence Score, ER, PR, or HER2 by Oncotype DX. CCNB1 and AURKA were significantly higher in Hispanic women. These tumor differences may help explain breast cancer outcome differences between the two ethnicities.
与非西班牙裔白人女性相比，西班牙裔女性的乳腺癌死亡率更高。我们评估了通过Oncotype Dx测定的、新诊断乳腺癌的西班牙裔和非西班牙裔白人女性的增殖轴评分差异。我们根据年龄、分期和淋巴结状态对219名女性进行了匹配。与非西班牙裔白人相比，患有激素敏感、HER2阴性早期乳腺癌的西班牙裔女性的增殖轴评分更高。Oncotype DX检测的复发评分、雌激素受体（ER）、孕激素受体（PR）或HER2没有差异。细胞周期蛋白B1（CCNB1）和极光激酶A（AURKA）在西班牙裔女性中显著更高。这些肿瘤差异可能有助于解释这两个种族之间乳腺癌预后的差异。
